<DOC>
	<DOCNO>NCT01497912</DOCNO>
	<brief_summary>Patients type 1 diabetes increase risk vascular complication micro- macrocirculation . Hyperglycemia play major role development vascular complication , factor increase platelet adhesion aggregation , elevate level plasma fibrinogen , alter fibrin network structure , increase thrombin generation , dyslipidemia endothelial dysfunction may contribute . Lipid-lowering therapy statin effective prevention cardiovascular event individual increase risk . Statins seem exert beneficial effect hemostasis vasculature independent lipid-lowering property . The aim present study investigate effect intensive LDL-cholesterol-lowering therapy atorvastatin fibrin network permeability ( primary variable ) aspects hemostasis patient type 1 diabetes dyslipidemia . Furthermore , effect atorvastatin therapy skin microvascular function also investigate .</brief_summary>
	<brief_title>Treatment Effects Atorvastatin Hemostasis Skin Microcirculation Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>type 1 diabetes level plasma LDLcholesterol &gt; 2.5mmol/L and/or total cholesterol &gt; 4.5mmol/L History macrovascular event</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2005</verification_date>
</DOC>